<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151364">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01919489</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00068128</org_study_id>
    <secondary_id>(UTN) U1111-1139-2991</secondary_id>
    <nct_id>NCT01919489</nct_id>
  </id_info>
  <brief_title>Liraglutide Hospital Discharge Trial</brief_title>
  <official_title>A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide Versus Glargine Insulin for the Management of Patients With Type 2 Diabetes After Hospital Discharge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood glucose levels in hospitalized patients with diabetes are associated with
      increased risk of medical complications and death. Improved glucose control with insulin
      injections may improve clinical outcome and prevent some of the hospital complications.
      Increasing evidence indicates that incretin-based agents are safe and effective for the
      hospital management of patients with type 2 diabetes (T2D).

      Liraglutide is a once-daily human glucagon-like peptide (GLP-1) analogue approved for the
      treatment of T2D. Liraglutide has been shown to lower blood glucose, stimulate endogenous
      insulin secretion, decrease plasma glucagon levels, inhibit gastric emptying, reduce food
      intake and body weight and improve ß-cell function when administered subcutaneously.
      Liraglutide increases insulin secretion in a glucose-dependent manner (i.e., only when
      plasma glucose levels are elevated), resulting in low-risk of hypoglycemia when used as
      monotherapy. When compared to insulin glargine therapy, the use of GLP-1 has resulted in
      comparable reduction in HbA1c level, lower rates of hypoglycemia and less weight gain.  No
      prospective studies; however, have compared the efficacy and safety of liraglutide in the
      hospital setting or after hospital discharge.

      The primary objective is to compare the safety and efficacy of liraglutide (Victoza®) versus
      glargine insulin in combination to oral anti-diabetic agents (OADs: metformin,
      sulfonylureas, nateglinide, repaglinide or pioglitazone) on glycemic control after 26 weeks
      of treatment in medicine patients with T2D after hospital discharge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim: To determine whether treatment with liraglutide (Victoza®) will result in
      similar glycemic control (HbA1c at 26 weeks) and a lower rate of hypoglycemic events
      compared to treatment with glargine (Lantus®) in non-surgical patients with T2D after
      hospital discharge. Patients with poorly controlled (HbA1c &gt;7%-10%) T2D treated with diet or
      oral antidiabetic agents (insulin naïve) prior to admission will be randomized to
      liraglutide and glargine in combination to OADs at hospital discharge.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>After discharge, 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine differences in HbA1c concentration at 26 weeks from discharge between liraglutide and glargine insulin therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting and postprandial blood glucose (BG) concentration</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine differences in BG concentration between liraglutide and glargine insulin therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic episodes</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of hypoglycemic events (&lt;70 mg/dl) and severe hypoglycemic events (&lt;40 mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7.0% and no hypoglycemia</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percent of patients with 26 week HbA1c &lt;7.0% and no hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7.0% and no weight gain</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of patients with 26 week HbA1c &lt;7.0% and no weight gain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c &lt;7.0% and no hypoglycemia</measure>
    <time_frame>After discharge, average 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percent of patients with 12 week HbA1c &lt;7.0% and no hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight and BMI</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in body weight and BMI after 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily dose of insulin</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the total daily dose of insulin needed in the group receiving glargine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cardiovascular risk factors including changes in blood pressure, heart rate, and lipid profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency room visits and readmissions</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of emergency room visits and hospital readmissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure</measure>
    <time_frame>After discharge, average 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Acute renal failure during the 26-week follow-up defined as a clinical diagnosis of acute renal failure with documented new-onset abnormal renal function (increment in creatinine &gt; 0.5 mg/dL from baseline)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide + OADs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liraglutide once daily in combination to oral anti-diabetic agents (OADs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glargine + OADs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glargine once daily in combination to oral anti-diabetic agents (OADs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide + OADs</intervention_name>
    <description>Liraglutide subcutaneously daily</description>
    <arm_group_label>Liraglutide + OADs</arm_group_label>
    <other_name>Victoza® + OADs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine + OADs</intervention_name>
    <description>Glargine once daily subcutaneously</description>
    <arm_group_label>Glargine + OADs</arm_group_label>
    <other_name>Glargine (Lantus®) + OADs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between the ages of 18 and 80 years discharged after hospital
             admission from general medicine services (non-surgical and non-ICU setting).

          2. Admission HbA1c between 7% and 10%

          3. Patients with T2D treated with diet alone or with oral antidiabetic agents
             (metformin, sulfonylureas, repaglinide, nateglinide, dipeptidyl peptidase-4 (DPP-4)
             inhibitors, pioglitazone) as monotherapy or in combination therapy (excluding GLP-1
             receptor agonists) prior to admission.

          4. Subjects with a hospital admission BG between 140 mg and &lt; 400 mg/dL without
             laboratory evidence of diabetic ketoacidosis (serum bicarbonate &lt; 18 mEq/L or
             positive serum or urinary ketones).

          5. BMI &gt; 25 Kg/m2 and &lt; 45 Kg/m2

        Exclusion Criteria:

          1. Age &lt; 18 or &gt; 80 years.

          2. Subjects with increased BG concentration, but without a history of diabetes (stress
             hyperglycemia)

          3. Subjects with a history of type 1 diabetes (suggested by BMI &lt; 25 Kg/m2 requiring
             insulin therapy   or with a history of diabetic ketoacidosis and hyperosmolar
             hyperglycemic state, or ketonuria).

          4. Treatment with insulin or GLP-1 analogs during the past 3 months prior to admission.

          5. Patients that required ICU care during the hospital admission

          6. Recurrent severe hypoglycemia or hypoglycemic unawareness.

          7. Subjects with gastrointestinal obstruction, gastroparesis or those expected to
             require gastrointestinal suction.

          8. History of medullary thyroid cancer or multiple endocrine neoplasia

          9. Patients with acute or chronic pancreatitis, pancreatic cancer or gallbladder
             disease.

         10. Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage
             liver disease, portal hypertension) and elevated ALT and AST &gt; 3 times upper limit of
             normal, or significantly impaired renal function (GFR &lt; 45 ml/min).

         11. Treatment with oral or injectable corticosteroid, parenteral nutrition and
             immunosuppressive treatment.

         12. Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

         13. Female subjects who are pregnant or breast feeding at time of enrollment into the
             study.

         14. Females of childbearing potential who are not using adequate contraceptive methods
             (as required by local law or practice).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo E Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University SOM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillermo E Umpierrez, MD</last_name>
    <phone>404-778-1665</phone>
    <email>geumpie@emory.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco J Pasquel, MD</last_name>
    <phone>404 778 1697</phone>
    <email>fpasque@emory.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillermo E Umpierrez, MD</last_name>
      <phone>404-778-1665</phone>
      <email>geumpie@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Francisco J Pasquel, MD</last_name>
      <phone>404 778 1697</phone>
      <email>fpasque@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Guillermo Umpierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco J Pasquel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dawn Smiley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Newton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farnoosh Farrokhi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sol Jacobs, MD</last_name>
      <email>sjacob5@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Sol Jacobs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Perez-Perez, MD</last_name>
      <email>APerez@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Antonio Perez-Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco J Novoa, MD</last_name>
      <email>fnovoa@dcmq.ulpgc.es</email>
    </contact>
    <investigator>
      <last_name>Francisco J Novoa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfonso Calle, MD</last_name>
      <email>acalle.edu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alfonso Calle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricardo Gomez-Huelgas, MD</last_name>
      <email>ricardogomezhuelgas@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Gomez-Huelgas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <zip>40002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fernando Gomez-Peralta, MD</last_name>
      <email>Fernando Gomez Peralta &lt;fgomezperalta@gmail.com&gt;</email>
    </contact>
    <investigator>
      <last_name>Fernando Gomez-Peralta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>July 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Incretins</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Glargine</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>basal insulin</keyword>
  <keyword>hospital discharge</keyword>
  <keyword>inpatient diabetes</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
